Extracellular stability of nanoparticulate drug carriers
- 520 Downloads
Nanoparticulate (NP) drug carrier systems are attractive vehicles for selective drug delivery to solid tumors. Ideally, NPs should evade clearance by the reticuloendothelial system while maintaining the ability to interact with tumor cells and facilitate cellular uptake. Great effort has been made to fulfill these design criteria, yielding various types of functionalized NPs. Another important consideration in NP design is the physical and functional stability during circulation, which, if ignored, can significantly undermine the promise of intelligently designed NP drug carriers. This commentary reviews several NP examples with stability issues and their consequences, ending in a discussion of experimental methods for reliable prediction of NP stability.
KeywordsNanomedicine Nanoparticles Drug delivery Stability Sensitivity
This work was supported by NSF DMR-1056997, a Grant from the Lilly Endowment, Inc. to College of Pharmacy, Purdue University, and Intramural Research Program (Global RNAi Carrier Initiative) of Korea Institute of Science and Technology. This study was also partly supported by the NIH/NCRR-Indiana Clinical and Translational Sciences Institute Pre-doctoral Fellowship (TL1 RR025759, PI: A. Shekhar) to KCL.
- De Smet, M., E. Heijman, S. Langereis, N.M. Hijnen, and H. Grüll. 2011. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: An in vivo proof-of-concept study. Journal of Controlled Release 150: 102–110.PubMedCrossRefGoogle Scholar
- Desai, N. 2008. Nab technology: A drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting drug delivery report, winter 2007/2008, 37–41.Google Scholar
- Ernsting, M.J., M. Murakami, E. Undzys, A. Aman, B. Press, and S.D. Li. 2012. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, abraxane, in mouse tumor models with significant control of metastases. Journal of Controlled Release 162: 575–581.PubMedCrossRefGoogle Scholar
- Gu, F., L. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno, R. Langer, and O.C. Farokhzad. 2008. From the cover: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proceedings of the National Academy of Sciences 105: 2586–2591.CrossRefGoogle Scholar
- Hamaguchi, T., K. Kato, H. Yasui, C. Morizane, M. Ikeda, H. Ueno, K. Muro, Y. Yamada, T. Okusaka, K. Shirao, Y. Shimada, H. Nakahama, and Y. Matsumura. 2007. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. British Journal of Cancer 97: 170–176.PubMedCentralPubMedCrossRefGoogle Scholar
- Nyman, D.W., K.J. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M.J. Hawkins, and D.D. Von Hoff. 2005. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. Journal of Clinical Oncology 23: 7785–7793.PubMedCrossRefGoogle Scholar
- Sherwood, L. 2011. Human physiology: From cells to systems. Belmont, CA: Cengage Learning.Google Scholar